Skip to main content
Figure 1 | BMC Cancer

Figure 1

From: Activity of EGFR-tyrosine kinase and ALK inhibitors for EML4–ALK-rearranged non–small–cell lung cancer harbored coexisting EGFRmutation

Figure 1

Histology of the primary tumour. (A) and (B) shows a papillary adenocarcinoma (hematoxylin and eosin 200× magnification), (C) a mucin stain shows positive for both signet-ring and papillary morphology (PAS, 400× magnification). (D) immunohistochemical analysis of lung adenocarcinoma specimens with EML4-ALK fusion using a monoclonal anti-TTF-1 antibody (200× magnification).

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us